The Good News About AMD Prevention and Early Intervention - Top-Institutions - MDSpire

The Good News About AMD Prevention and Early Intervention

AMD severity is measured on a spectrum, and the sooner doctors, patients, and caregivers are aware of its presence, the sooner everyone can work together to protect against it. 

  • By

  • Pamela Lowe, OD

  • March 2, 2026

  • 7 min

Share

Top Institutions in Optometry

Brief introduction explaining scope and methodology.

  • #1

    National Eye Institute (NEI)
    National Eye Institute (NEI)

    Bethesda, MD

    Key Differentiators

    • Ophthalmology
    • Vision Research
    • Retinal Diseases

  • #2

    Bascom Palmer Eye Institute, University of Miami
    Bascom Palmer Eye Institute, University of Miami

    Miami, FL

    Key Differentiators

    • Ophthalmology
    • Retina
    • Clinical Research

  • #3

    Massachusetts Eye and Ear Infirmary, Harvard Medical School
    Massachusetts Eye and Ear Infirmary, Harvard Medical School

    Boston, MA

    Key Differentiators

    • Ophthalmology
    • Retina
    • Vision Science

  • #4

    Johns Hopkins Wilmer Eye Institute
    Johns Hopkins Wilmer Eye Institute

    Baltimore, MD

    Key Differentiators

    • Ophthalmology
    • Retina
    • Clinical Trials

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Ophthalmology
    • Retina
    • Preventive Medicine

Original Source(s)

The Good News About AMD Prevention and Early Intervention

  • by Pamela Lowe, OD

  • March 2, 2026

Related Content

Viewpoint: 60 Years: A Legacy of Optometric Learning

Paging through the past, I was particularly taken by the first issue’s “View” section, where the then publishers posed a series of questions. 

Eric Souied Joins SeaBeLife

French biotechnology company, SeaBeLife, welcomes AMD specialist to its scientific committee

  • March 9, 2026

  • 2 min
Biologics Tied to Lower Eye Risk in Psoriasis

Real-world data suggest lower rates of ocular surface disease with biologics vs nonbiologic systemic therapy.